Dana-Farber Cancer Institute; Harvard Medical School Boston, Massachusetts
Learning Objectives:
Describe the molecular characteristics and prognostic impact of HER2 overexpression in breast cancer
Identify emerging therapies in early and advanced HER2+ BC along with key updates to clinical data
Summarize adverse effects (AEs) expected for current and emerging therapies in HER2-positive breast cancer and describe preventive and management strategies for AEs